Lilly set to acquire Alnara Pharmaceuticals
pharmafile | July 5, 2010 | News story | Research and Development, Sales and Marketing | Alnara, Liprotamase, cystic fibrosis, enzyme replacement therapy, lilly
Lilly is to acquire US-based biotech firm Alnara and will take hold of its lead product Liprotamase for pancreatic enzyme replacement therapy.
Liprotamase is currently under FDA review and is a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). This insufficiency can have multiple causes that include cystic fibrosis, chronic pancreatitis, pancreatectomy and other conditions.
Bryce Carmine, executive VP of Lilly and president of Lilly BioMedicines, said: “The acquisition of Alnara provides Lilly with a promising entry into enzyme replacement therapy – an area with unmet medical needs as well as opportunities for novel compounds that give patients additional treatment options.
“Alnara has been very successful in the development of Liprotamase – as indicated by its recent submission to the FDA – and we look forward to partnering with Alnara’s experts during the regulatory review process.”
Patients with pancreatic insufficiency cannot properly digest and absorb fat, protein, and carbohydrates, preventing adequate nutrient absorption.
PERT treatment involves the administration of three pancreatic enzymes with the aim of encouraging greater pancreatic efficiency.
One of the more recent treatments in development for PERT was Altus Therapeutics’ Trizytec, but development was halted after disappointing phase III results.
Results from an international, phase III, open-label, long-term safety study of Liprotamase presented at the North American Cystic Fibrosis Conference (NACFC) in October last year established its initial safety and nutritional benefits.
Alexey Margolin, chief executive of Alnara, said: “Our agreement with Lilly is an important development as we move Liprotamase through FDA regulatory review.
“Lilly’s deep expertise in the US pharmaceutical business, including regulatory affairs and the development of innovative compounds that address unmet medical needs, created a natural fit and could allow for opportunities in markets beyond cystic fibrosis.”
Financial terms of the agreement were not disclosed.
Ben Adams
Related Content
Vertex presents promising new data from cystic fibrosis trials
Vertex Pharmaceuticals has presented new data showing the clinical and quality-of-life benefits of its cystic …
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …
Arcturus Therapeutics provides update on OTC deficiency and CF programmes
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine …
